AbbVie Inc
ABBV186.960USD
Today
-7.33%
5 Days
-8.92%
1 Month
-11.61%
6 Months
-3.77%
Year to Date
+5.21%
1 Year
+9.97%
Agency Rating
Analyst Rating
Peer Comparison
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
News
Berenberg raises AbbVie PT on higher immunology drug sales
** Berenberg raises PT on drugmaker AbbVie ABBV.N to $195 from $165, citing higher immunology drug sales ** New PT is a 8.7% downside to stock's last close** Brokerage says AbbVie knows the autoimmune market well ** Says co reduced exposure to antirheumatic drug Humira and bolstered cash flows t...
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
Feb 7 (Reuters) - AbbVie ABBV.N said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.AbbVie and co-developer Pfizer's PFE.N drug, Emblaveo, is approved in combination with an...
